Background Programmed death ligand 1 (PD-L1) targeting immunotherapies, as
pembrolizumab and nivolumab, have significantly improved outcome in patients with non …

Background Pembrolizumab plus pemetrexed–platinum led to superior overall survival and
progression-free survival, and a higher proportion of patients with a confirmed complete or …

Inhibitory antibodies targeting programmed death protein 1 (PD-1) and programmed death
ligand 1 (PD-L1) have resulted in improved outcomes for many patients with metastatic non …

Pembrolizumab, a humanized monoclonal antibody against programmed death 1 (PD‐1),
has been shown to improve overall survival (OS) in patients with previously treated …

Purpose Lung cancer is one of the most common types of cancer, resulting in approximately
1.8 million deaths worldwide. Immunotherapy using checkpoint inhibitors has become …

The combination of programmed cell death-1 (PD-1)/programmed death ligand-1 (PD-L1)
inhibitors with chemotherapy has emerged as a promising therapeutic option for advanced …

Background The use and approval of immune checkpoint inhibitors for the treatment of non-
small cell lung cancer (NSCLC) depends on PD-L1 expression in the tumor tissue …

Background. There has been much innovation in the treatment of non–small cell lung cancer
(NSCLC) in recent years. In particular, use of immuno-oncology (IO) therapies has been …

The FDA has expanded the indication for pemetrexed (Alimta) injection in combination with
pembrolizumab (Keytruda) and platinum-based chemotherapy for the first-line treatment of …